Logotype for Autolus Therapeutics plc

Autolus Therapeutics (AUTL) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Autolus Therapeutics plc

Q3 2026 earnings summary

10 Nov, 2026

Executive summary

  • Q3 AUCATZYL net product revenue was $41.238M, up 95% YoY; 9M revenue reached $113.1M, up 122%.

  • FY2026 revenue is expected to meet or exceed $150M; Q3 gross margin reached 57%.

Financial highlights

  • Q3 net product revenue was $41.238M vs. $21.144M; cost of sales was $17.927M vs. $28.643M.

  • R&D expense was $30.900M vs. $27.892M; SG&A was $35.946M vs. $36.280M.

  • Operating loss narrowed to $43.535M from $71.621M; net loss narrowed to $55.1M from $79.1M.

  • Nine-month net loss was $165.8M; operating cash use fell to $108.9M from $216.2M YoY.

  • Q3 basic and diluted loss per share was $0.21 vs. $0.30 YoY.

Outlook and guidance

  • FY2026 AUCATZYL revenue is expected to meet or exceed $150M, the upper end of prior guidance.

  • Gross margin is expected to improve with higher volumes and cost efficiencies; the peak gross-margin target is 65–70%.

  • Current plans, anticipated AUCATZYL proceeds and $100M from the first and second Perceptive tranches are projected to fund operations into Q2 2028.

  • BOBCAT enrollment is expected to finish in Q1 2027; initial data presentation is planned for October 2027, with up to 24 patients and at least 12 with 12+ months of follow-up.

  • R&D expense is expected to increase substantially as additional trials begin; operating losses are expected to continue.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Autolus Therapeutics